Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Absci Corp (ABSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ABSI (1-star) is a SELL. SELL since 2 days. Profits (-14.05%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.34
1 Year Target Price $8.34
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.58% | Avg. Invested days 19 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 432.69M USD | Price to earnings Ratio - | 1Y Target Price 8.34 |
Price to earnings Ratio - | 1Y Target Price 8.34 | ||
Volume (30-day avg) 9 | Beta 2.04 | 52 Weeks Range 2.01 - 6.33 | Updated Date 08/15/2025 |
52 Weeks Range 2.01 - 6.33 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.21 | Actual -0.24 |
Profitability
Profit Margin - | Operating Margin (TTM) -5293.93% |
Management Effectiveness
Return on Assets (TTM) -31.26% | Return on Equity (TTM) -57.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 322642056 | Price to Sales(TTM) 104.56 |
Enterprise Value 322642056 | Price to Sales(TTM) 104.56 | ||
Enterprise Value to Revenue 77.97 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 144228992 | Shares Floating 112238413 |
Shares Outstanding 144228992 | Shares Floating 112238413 | ||
Percent Insiders 9.25 | Percent Institutions 59.59 |
Upturn AI SWOT
Absci Corp
Company Overview
History and Background
Absci Corp, founded in 2011, is a biotechnology company focused on AI-powered drug discovery. It combines synthetic biology and machine learning to design and develop novel biologics. The company went public in July 2021.
Core Business Areas
- Integrated Drug Creation Platform: Absci's core offering is its AI-powered Integrated Drug Creation Platform, which leverages its data and AI models to design optimal biologics.
- Therapeutic Programs: Absci develops its own pipeline of therapeutic antibody candidates, and partners with pharmaceutical companies.
Leadership and Structure
Sean McClain is the founder and CEO. The company has a typical corporate structure with departments for R&D, Engineering, Finance, and Marketing.
Top Products and Market Share
Key Offerings
- Integrated Drug Creation Platform: Absci's AI-powered platform allows partner's to design and develop custom drugs. Revenue is generated through partnerships, licensing agreements, and milestone payments. Competitors include companies like Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) which also use AI in drug discovery but don't integrate in the same fashion with wet lab and synthetic biology.
- Therapeutic Antibody Candidates: Absci develops and out-licenses novel biologics. No significant revenue at present. Competitors include any company developing antibody therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is rapidly adopting AI and machine learning to accelerate drug discovery and development. Personalized medicine and advanced biological therapies are key trends.
Positioning
Absci is positioned as a leader in AI-driven drug creation, aiming to disrupt traditional antibody discovery approaches. Their integrated platform is their key competitive advantage.
Total Addressable Market (TAM)
The total addressable market for drug discovery is estimated to be hundreds of billions of dollars annually. Absci is positioned to capture a portion of this market by offering faster and more efficient drug discovery services.
Upturn SWOT Analysis
Strengths
- Proprietary AI-powered drug creation platform
- Integration of synthetic biology and machine learning
- Potential for faster and more efficient drug discovery
- Experienced management team
- Strategic Partnerships
Weaknesses
- Relatively young company
- Limited revenue to date
- Dependence on partnerships for revenue
- Technological risk associated with AI
- Relatively small market cap means high stock volatility
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing own pipeline of therapeutic candidates
- Growing adoption of AI in drug discovery
- Expanding the platform to new modalities
- Significant number of drugs are reaching patent expiry.
Threats
- Competition from other AI-driven drug discovery companies
- Regulatory hurdles for new drug approvals
- Failure of partnerships
- Technical setbacks in AI development
- Economic downturns affecting pharmaceutical investment
Competitors and Market Share
Key Competitors
- RXRX
- SDGR
- CDXS
- CRIS
Competitive Landscape
Absci's advantage lies in its integrated platform. Competitors have specific niches. Absci needs to demonstrate commercial success to solidify its position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's relatively recent IPO. Revenue growth has been observed in the last few years, which includes revenue from partnership payments.
Future Projections: Analyst projections suggest significant revenue growth in the coming years as partnerships mature and new therapeutic candidates advance.
Recent Initiatives: Recent initiatives include expanding partnerships with pharmaceutical companies and advancing internal therapeutic programs.
Summary
Absci is a young biotechnology company with a promising AI-powered drug creation platform. Its strengths include innovative technology and strategic partnerships. The company needs to demonstrate commercial success and manage technological risks. Absci operates in a competitive landscape but has potential for significant growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is subject to change. All data taken from public sources and should be verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Absci Corp
Exchange NASDAQ | Headquaters Vancouver, WA, United States | ||
IPO Launch date 2021-07-22 | Founder, CEO, President & Director Mr. Sean McClain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 156 | Website https://www.absci.com |
Full time employees 156 | Website https://www.absci.com | ||
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.